New PD-L1 Inhibitor Could Make Mesothelioma Immunotherapy Safer
A new PD-L1 inhibitor may be on the horizon for people with malignant mesothelioma. A Phase I trial suggests it may be safer than some previous immunotherapy drugs. PD-L1 is a protein that helps mesothelioma cancer cells hide from the immune system. Several of the most promising immunotherapy drugs for mesothelioma block PD-L1. But the new PD-L1 inhibitor is different. CX-072 (pacmilimab) has the ability to specifically target the tumor. This could reduce the risk for dangerous side effects since normal cells are less likely to be affected. San Francisco-based CytomX Therapeutics developed CX-072 and a team of international researchers has been studying it. This week, they released the findings of their Phase I trial. The trial included patients with … Continue reading New PD-L1 Inhibitor Could Make Mesothelioma Immunotherapy Safer
Could ONCOS-102 Be a New First-Line Mesothelioma Treatment?
A new first-line mesothelioma treatment has moved a step closer to becoming reality. New data show that the immunotherapy drug ONCOS-102 continues to look promising, nine months into a Phase I/II clinical trial. The drug was especially helpful to mesothelioma patients who had not yet had any treatment. Norweigian drug maker Targovax made the announcement earlier this month. ONCOS-102 is an experimental drug based on a modified virus. The virus helps it target mesothelioma cells while leaving healthy cells alone. The latest results show ONCOS-102 helps standard mesothelioma chemotherapy work better. Targovax says the next step will be a larger test of the combination as a first-line mesothelioma treatment. Clinical Trial of ONCOS-102 The power of ONCOS-102 comes from the … Continue reading Could ONCOS-102 Be a New First-Line Mesothelioma Treatment?